← Back to Search

Ketone Supplement

D-β-hydroxybutyric acid with R-1,3-butanediol for Diabetes

N/A
Waitlist Available
Led By Jonathan Little, PhD
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up start of enrolment to completion of enrolment

Summary

This trial will investigate whether drinking ketone supplements can help improve blood sugar control and influence how cells function in people with type 2 diabetes.

Eligible Conditions
  • Diabetes
  • High Blood Sugar
  • Ketosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days -5 through 9 (5 days of baseline and first 9 days of intervention period) and days 77 through 90 (last 2 weeks)
This trial's timeline: 3 weeks for screening, Varies for treatment, and days -5 through 9 (5 days of baseline and first 9 days of intervention period) and days 77 through 90 (last 2 weeks) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To determine the feasibility of conducting a randomized controlled trial (RCT) on the effects of consumption of a ketone supplement in adults with type 2 diabetes in free-living environment for 90 days: Recruitment rate of participants into the trial
To determine the feasibility of conducting such an RCT: Compliance as measured by the self-reported volume of ketone supplement drink consumed
To determine the feasibility of conducting such an RCT: Retention as measured by the number of participants that complete the study
Secondary study objectives
Cravings
Gastrointestinal distress
Hematology panel
+17 more
Other study objectives
Intervention acceptability
Viability of methods

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Exogenous Ketone SupplementExperimental Treatment1 Intervention
Participants will be instructed to consume a total of 711 mL of the exogenous ketone supplement drink (for a total of 30 g of beta-hydroxybutyrate) per day (3 doses at 237 mL containing 10 g of beta-hydroxybutyrate each) for a period of 90 days.
Group II: Inert placeboPlacebo Group1 Intervention
Participants will be instructed to consume an equivalent volume (711 mL) of taste- and volume-matched placebo per day (3 doses at 237 mL) for 90 days.

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,466 Previous Clinical Trials
2,485,436 Total Patients Enrolled
9 Trials studying Diabetes
343 Patients Enrolled for Diabetes
Jonathan Little, PhDPrincipal InvestigatorUniversity of British Columbia
6 Previous Clinical Trials
325 Total Patients Enrolled
~6 spots leftby Nov 2025